169 related articles for article (PubMed ID: 35213370)
1. Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.
Chan CK; Pettigrew C; Soldan A; Zhu Y; Wang MC; Albert M; Rosenberg PB;
J Alzheimers Dis; 2022; 86(3):1415-1426. PubMed ID: 35213370
[TBL] [Abstract][Full Text] [Related]
2. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
[TBL] [Abstract][Full Text] [Related]
3. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
[TBL] [Abstract][Full Text] [Related]
4. White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease.
Misquitta K; Dadar M; Louis Collins D; Tartaglia MC;
Neuroimage Clin; 2020; 28():102367. PubMed ID: 32798911
[TBL] [Abstract][Full Text] [Related]
5. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
[TBL] [Abstract][Full Text] [Related]
6. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
7. Neuropathologic Correlates of White Matter Hyperintensities in a Community-Based Cohort of Older Adults.
Arfanakis K; Evia AM; Leurgans SE; Cardoso LFC; Kulkarni A; Alqam N; Lopes LF; Vieira D; Bennett DA; Schneider JA
J Alzheimers Dis; 2020; 73(1):333-345. PubMed ID: 31771057
[TBL] [Abstract][Full Text] [Related]
8. White matter hyperintensity patterns: associations with comorbidities, amyloid, and cognition.
Bachmann D; von Rickenbach B; Buchmann A; Hüllner M; Zuber I; Studer S; Saake A; Rauen K; Gruber E; Nitsch RM; Hock C; Treyer V; Gietl A
Alzheimers Res Ther; 2024 Apr; 16(1):67. PubMed ID: 38561806
[TBL] [Abstract][Full Text] [Related]
9. The Longitudinal Assessment of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimer's Disease and Their Association With White Matter Hyperintensities in the National Alzheimer's Coordinating Center's Uniform Data Set.
Anor CJ; Dadar M; Collins DL; Tartaglia MC
Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Jan; 6(1):70-78. PubMed ID: 32389747
[TBL] [Abstract][Full Text] [Related]
10. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
[TBL] [Abstract][Full Text] [Related]
11. Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.
Ronat L; Hanganu A; Chylinski D; Van Egroo M; Narbutas J; Besson G; Muto V; Schmidt C; Bahri MA; Phillips C; Salmon E; Maquet P; Vandewalle G; Collette F; Bastin C
J Neurol; 2024 Apr; 271(4):2067-2077. PubMed ID: 38114820
[TBL] [Abstract][Full Text] [Related]
12. Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Shirzadi Z; Schultz SA; Yau WW; Joseph-Mathurin N; Fitzpatrick CD; Levin R; Kantarci K; Preboske GM; Jack CR; Farlow MR; Hassenstab J; Jucker M; Morris JC; Xiong C; Karch CM; Levey AI; Gordon BA; Schofield PR; Salloway SP; Perrin RJ; McDade E; Levin J; Cruchaga C; Allegri RF; Fox NC; Goate A; Day GS; Koeppe R; Chui HC; Berman S; Mori H; Sanchez-Valle R; Lee JH; Rosa-Neto P; Ruthirakuhan M; Wu CY; Swardfager W; Benzinger TLS; Sohrabi HR; Martins RN; Bateman RJ; Johnson KA; Sperling RA; Greenberg SM; Schultz AP; Chhatwal JP;
JAMA Neurol; 2023 Dec; 80(12):1353-1363. PubMed ID: 37843849
[TBL] [Abstract][Full Text] [Related]
13. Topographical differences in white matter hyperintensity burden and cognition in aging, MCI, and AD.
Kamal F; Morrison C; Maranzano J; Zeighami Y; Dadar M
Geroscience; 2023 Feb; 45(1):1-16. PubMed ID: 36229760
[TBL] [Abstract][Full Text] [Related]
14. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
[TBL] [Abstract][Full Text] [Related]
15. White matter hyperintensity load varies depending on subjective cognitive decline criteria.
Morrison C; Dadar M; Villeneuve S; Ducharme S; Collins DL
Geroscience; 2023 Feb; 45(1):17-28. PubMed ID: 36401741
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychiatric Correlates of Small Vessel Disease Progression in Incident Cognitive Decline: Independent and Interactive Effects.
Kan CN; Gyanwali B; Hilal S; Ng KP; Venketasubramanian N; Chen CL; Xu X
J Alzheimers Dis; 2020; 73(3):1053-1062. PubMed ID: 31884482
[TBL] [Abstract][Full Text] [Related]
17. White matter hyperintensities and their relationship to cognition: Effects of segmentation algorithm.
Tubi MA; Feingold FW; Kothapalli D; Hare ET; King KS; Thompson PM; Braskie MN;
Neuroimage; 2020 Feb; 206():116327. PubMed ID: 31682983
[TBL] [Abstract][Full Text] [Related]
18. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
19.
Mirza SS; Saeed U; Knight J; Ramirez J; Stuss DT; Keith J; Nestor SM; Yu D; Swardfager W; Rogaeva E; St George Hyslop P; Black SE; Masellis M;
Neurology; 2019 Nov; 93(19):e1807-e1819. PubMed ID: 31575706
[TBL] [Abstract][Full Text] [Related]
20. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
